Entering text into the input field will update the search result below

Ayala says interim phase 2/3 results show desmoid tumor shrinking with its AL102 inhibitor

Jul. 05, 2022 10:48 AM ETAyala Pharmaceuticals, Inc. (AYLA)By: Anuron Mitra, SA News Editor
  • Ayala Pharmaceuticals (NASDAQ:AYLA) on Tuesday announced what it deemed to be positive interim results from part A of its ongoing phase 2/3 trial evaluating its inhibitor AL102 in desmoid tumors, which are a type of noncancerous growth that can

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Related Stocks

SymbolLast Price% Chg
Ayala Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.